Prostate Cancer Screening Labelle FL

Prostate cancer screening consists of diagnostic tests that can assist with early detection of prostate cancer. Screening may involve a digital rectal exam, prostate-sspecific antigen (PSA) blood test, or a transrectal ultrasound. See below to learn more and to gain access to qualified oncologists in Labelle, FL who provide prostate cancer screening.

Phyliss L. Murphy
(407) 382-0682
11500 University Blvd
Orlando, FL
Boon Chew, MD
(386) 254-4212
303 N Clyde Morris Blvd
Daytona Beach, FL
Eloy Roman
(305) 856-6753
3659 S Miami Ave
Miami, FL
Jennifer Lynn Ball
(727) 216-1141
1840 Mease Dr
Safety Harbor, FL
Jorge Antunez De Mayolo, MD
305-854-8080
3661 S Miami Ave Ste 301
Miami, FL
Michael J Dattoli, MD
(941) 957-4926
2803 Fruitville Rd
Sarasota, FL
Pablo Ferraro, MD
(954) 430-6868
801 N Flamingo Rd
Pembroke Pines, FL
Kenneth Richard Olivier, MD
352-256-0316
PO Box 100385shands Cancer Ctr
Gainesville, FL
Geethanjali Kumar Akula, MD
407-316-8052
52 W Gove St
Orlando, FL
Leon Suissa
(305) 757-2226
1380 Ne Miami Gardens Dr
Miami, FL
Data Provided by:
   

All about the PSA Test

The PSA (Prostate-Specific Antigen) test is one of two primary screening tools for prostate cancer. This simple blood test measures the level of PSA, a protein produced in the prostate, present in a man's body. Men typically have an initial PSA screening at 50, or earlier if there's a family history of prostate cancer.

Physicians measure PSA in nanograms per milliliter. An elevated PSA doesn't diagnose cancer and doesn't mean a man has prostate cancer; it just suggests further evaluation. Other medical conditions can also raise PSA levels. A PSA test and additional diagnostic tools help detect small tumors, however, experts say it does not necessarily reduce a man's chance of dying of prostate cancer.

An increase in PSA is the strongest single predictor of prostate cancer risk, and a high PSA score followed by a lower PSA score is not uncommon, even in men who do have cancer. However, PSA progression does predict poor overall survival rates in men with mestacized prostate cancer (meaning it has spread beyond the prostate). The PSA test is actually a better predictor of prostate cancer risk in African-American men with family histories compared to European- American men.

There is controversy over the value of PSA screenings. This spring, researchers released the results of a large-scale study that began in 1992 to evaluate whether or not the PSA test benefited men. In the subsequent media coverage of the results, the news varied widely depending on who was doing the reporting...

Click here to read more from Quality Health